Will the first vaccine against Lyme disease be launched together with Pfizer?

Valneva is currently going through the most exciting phase in its corporate history. The strategic decision to separate from the low-margin third-party business and fully focus on its own vaccines, such as the Chikungunya vaccine IXCHIQ, is absolutely the right move in my opinion. Although the recent net loss may be disturbing at first glance, the steady growth of its own products demonstrates a high level of operational stability. Valneva impressively shows that biotech can occupy and monetize lucrative niche markets. This established core business...